

CARCINOMA OF THE CONJUNCTIVA STAGING FORM

| CLINICAL <i>Extent of disease before any treatment</i> | STAGE CATEGORY DEFINITIONS | | PATHOLOGIC <i>Extent of disease through completion of definitive surgery</i> | | | | | | | | | |
|---|---|---|--|----------------|-------|---|---------------------------------------|---|--|---|---|--|
| <input type="checkbox"/> y clinical – staging completed after neoadjuvant therapy but before subsequent surgery | TUMOR SIZE: _____ | LATERALITY: <input type="checkbox"/> left <input type="checkbox"/> right <input type="checkbox"/> bilateral | <input type="checkbox"/> y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery | | | | | | | | | |
| <input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> Tis <input type="checkbox"/> T1 <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4 <input type="checkbox"/> T4a <input type="checkbox"/> T4b <input type="checkbox"/> T4c <input type="checkbox"/> T4d | PRIMARY TUMOR (T) Primary tumor cannot be assessed No evidence of primary tumor Carcinoma <i>in situ</i> Tumor 5 mm or less in greatest dimension Tumor more than 5 mm in greatest dimension, without invasion of adjacent structures Tumor invades adjacent structures (excluding the orbit) Tumor invades the orbit with or without further extension Tumor invades orbital soft tissues, without bone invasion Tumor invades bone Tumor invades adjacent paranasal sinuses Tumor invades brain | | <input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> Tis <input type="checkbox"/> T1 <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4 <input type="checkbox"/> T4a <input type="checkbox"/> T4b <input type="checkbox"/> T4c <input type="checkbox"/> T4d | | | | | | | | | |
| <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1 | REGIONAL LYMPH NODES (N) Regional lymph nodes cannot be assessed No regional lymph node metastasis Regional lymph node metastasis | | <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1 | | | | | | | | | |
| <input type="checkbox"/> M0 <input type="checkbox"/> M1 | DISTANT METASTASIS (M) No distant metastasis (no pathologic M0; use clinical M to complete stage group) Distant metastasis | | <input type="checkbox"/> M1 | | | | | | | | | |
| ANATOMIC STAGE • PROGNOSTIC GROUPS | | | | | | | | | | | | |
| CLINICAL | | PATHOLOGIC | | | | | | | | | | |
| No stage grouping is presently recommended | | No stage grouping is presently recommended | | | | | | | | | | |
| PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS) REQUIRED FOR STAGING: None CLINICALLY SIGNIFICANT: Ki-67 growth fraction _____ | | | General Notes: For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis. m suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM. | | | | | | | | | |
| Histologic Grade (G) (also known as overall grade) <table style="width: 100%;"> <tr> <th style="text-align: left;">Grading system</th> <th style="text-align: left;">Grade</th> </tr> <tr> <td><input type="checkbox"/> 2 grade system</td> <td><input type="checkbox"/> Grade I or 1</td> </tr> <tr> <td><input type="checkbox"/> 3 grade system</td> <td><input type="checkbox"/> Grade II or 2</td> </tr> <tr> <td><input type="checkbox"/> 4 grade system</td> <td><input type="checkbox"/> Grade III or 3</td> </tr> <tr> <td><input type="checkbox"/> No 2, 3, or 4 grade system is available</td> <td><input type="checkbox"/> Grade IV or 4</td> </tr> </table> | | | | Grading system | Grade | <input type="checkbox"/> 2 grade system | <input type="checkbox"/> Grade I or 1 | <input type="checkbox"/> 3 grade system | <input type="checkbox"/> Grade II or 2 | <input type="checkbox"/> 4 grade system | <input type="checkbox"/> Grade III or 3 | <input type="checkbox"/> No 2, 3, or 4 grade system is available |
| Grading system | Grade | | | | | | | | | | | |
| <input type="checkbox"/> 2 grade system | <input type="checkbox"/> Grade I or 1 | | | | | | | | | | | |
| <input type="checkbox"/> 3 grade system | <input type="checkbox"/> Grade II or 2 | | | | | | | | | | | |
| <input type="checkbox"/> 4 grade system | <input type="checkbox"/> Grade III or 3 | | | | | | | | | | | |
| <input type="checkbox"/> No 2, 3, or 4 grade system is available | <input type="checkbox"/> Grade IV or 4 | | | | | | | | | | | |

| | |
|------------------------------|---------------------------------|
| HOSPITAL NAME/ADDRESS | PATIENT NAME/INFORMATION |
|------------------------------|---------------------------------|

(continued on next page)

CARCINOMA OF THE CONJUNCTIVA STAGING FORM

ADDITIONAL DESCRIPTORS

Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- ☐ Lymph-Vascular Invasion Not Present (absent)/Not Identified
- ☐ Lymph-Vascular Invasion Present/Identified
- ☐ Not Applicable
- ☐ Unknown/Indeterminate

Residual Tumor (R)

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- ☐ RX Presence of residual tumor cannot be assessed
- ☐ R0 No residual tumor
- ☐ R1 Microscopic residual tumor
- ☐ R2 Macroscopic residual tumor

General Notes (continued):

y prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.

r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.

a prefix designates the stage determined at autopsy: aTNM.

surgical margins is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

neoadjuvant treatment is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

☐ Clinical stage was used in treatment planning (describe): _____

☐ National guidelines were used in treatment planning ☐ NCCN ☐ Other (describe): _____

Physician signature

Date/Time

HOSPITAL NAME/ADDRESS


PATIENT NAME/INFORMATION

(continued from previous page)

CARCINOMA OF THE CONJUNCTIVA STAGING FORM

Illustration

Indicate on diagram primary tumor and regional nodes involved.



HOSPITAL NAME/ADDRESS

PATIENT NAME/INFORMATION